Lorlatinib

본문 바로가기


Home > Product > Lorlatinib
Selling leads
Lorlatinib
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Lorlatinib (PF-06463922) is an ALK inhibitor modified from Crizotinib by Pfizer of the United States. This drug entered clinical trials in 2014 for the treatment of lung cancer as described in Chemicalbook. It is mainly targeted at patients with non-small cell lung cancer who are resistant to the first-generation ALK inhibitor crizotinib and the second-generation ALK inhibitors Ceritinib and Alectinib.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top